Trial
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Pediatric Cancer (Oncology)
Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Unclassified soft tissue sarcoma, and Other soft tissue neoplasms (excluding benign tumors).
A COG soft tissue sarcoma diagnosis, biology and banking protocol.
Patients enrolled on D9902 fall into one of three groups:
Category 1: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review stratum of D9902.
Category 2: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review and Biology/Banking strata of D9902.
Category 3: Patients NOT planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can only enroll on the Biology/Banking stratum of D9902. Pathology Central Review will not be performed for clinical purposes or to meet any of the research objectives, except to establish the bank. The enrolling investigator/institution will not receive a report back from COG regarding the submitted sample.
Age: patients must be < 50 years of age at the time of enrollment
Patients must have one of the following histologically-confirmed diagnoses: Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), unclassified soft tissue sarcoma that is too undifferentiated to be placed in a specific pathologic category in the WHO classification, and other soft tissue neoplasms, excluding benign tumors
Patients with malignant rhabdoid tumor, Ewing sarcoma/PNET, or ostogenic sarcoma of bone are NOT eligible for enrollment on D9902
Principal Investigator Name
Janice Olson, MD
Children's Cancer and Blood Disorders Program
Last Updated:
Wednesday, January 27, 2021 11:41:32 AM